Our strategic R&D centres
Our R&D centres
We are committed to our purpose of pushing the boundaries of science to deliver life changing medicines and we have built our business around it. We have three strategic R&D centres in Cambridge, UK, Gaithersburg, US, and Gothenburg, Sweden. We also have an active R&D presence in 40 other countries spanning the globe.
strategic R&D centres in the UK, US and Sweden
active R&D presence in other countries spanning the globe
employees work exclusively in R&D
Our new facility at the Cambridge Biomedical Campus (CBC) will become AstraZeneca’s largest R&D centre in the UK, with more than 2,000 people working across all our therapy areas, drug discovery platforms, development and commercialisation.
The power of our physical proximity to our neighbours in academia, healthcare and industry creates a porous environment where ideas and talent can be shared to drive innovation. Already the scale of our collaboration with others in the city is considerable. We have well over 200 partnerships as part of the Cambridge ecosystem; hundreds more in the wider UK life sciences cluster.
A unique, innovative and inclusive modern campus, just a short drive away from Washington, DC, our Gaithersburg facility is home to a diverse community of some 3,500 people, with the capacity to discover, develop, manufacture, and commercialise life changing medicines – all on one site.
With a team of world-renowned scientists, cutting-edge technology, and a collaborative, interactive and cross-functional scientific culture, it’s a great place to work and an exciting place to be. Our outstanding facilities and amenities promote wellness and a positive work-life balance, helping us attract and retain the best talent, while contributing to our business’s values-led and sustainable approach to R&D.
With more than 2,400 employees from 50 countries, our vibrant Gothenburg site helps support the entire life-cycle of AstraZeneca medicines, from drug discovery and clinical trials, through to global commercialisation and product maintenance. In 2017, we launched Lab4Life, creating an open and truly shared research environment that goes beyond the usual laboratory model. By breaking down traditional lab walls, automating processes and driving state of-the-art IT, we are creating novel ways of working to speed up delivery of new medicines.
Looking to the future, Gothenburg has initiated the creation of a new, global cluster for health and life sciences, as part of the GoCo Health Innovation City project, which includes the Gothenburg BioVentureHub. There are currently more than 30 external companies and one academic group co-locating with AstraZeneca at the heart of the Gothenburg site. By facilitating interactions between drug, device, diagnostics and digital health companies, we are creating a dynamic, creative and fertile environment for helping unlock the power of what science can do.